Oncotelic Therapeutics (Oncotelic Therapeutics) Debt-to-Equity : 1.04 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Debt-to-Equity?

Oncotelic Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.68 Mil. Oncotelic Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.90 Mil. Oncotelic Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $12.13 Mil. Oncotelic Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 1.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oncotelic Therapeutics's Debt-to-Equity or its related term are showing as below:

OTLC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.58 Max: 1.13
Current: 1.04

During the past 13 years, the highest Debt-to-Equity Ratio of Oncotelic Therapeutics was 1.13. The lowest was 0.06. And the median was 0.58.

OTLC's Debt-to-Equity is ranked worse than
88.06% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs OTLC: 1.04

Oncotelic Therapeutics Debt-to-Equity Historical Data

The historical data trend for Oncotelic Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics Debt-to-Equity Chart

Oncotelic Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.40

1.13

0.58

1.04

Oncotelic Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.58	0.63	0.99	0.99	1.04

Competitive Comparison of Oncotelic Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Oncotelic Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncotelic Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's Debt-to-Equity falls into.

Oncotelic Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oncotelic Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.675	+	1.898)	/	12.13
	=	1.04

Oncotelic Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.675	+	1.898)	/	12.13
	=	1.04

Oncotelic Therapeutics (OTCPK:OTLC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oncotelic Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301

Website

https://www.oncotelic.com

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Executives

Vuong Trieu	officer: CHIEF EXECUTIVE OFFICER	4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund	officer: CHIEF BUSINESS OFFICER	C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah	officer: CHIEF FINANCIAL OFFICER	10 AGUILA, ALISO VIEJO CA 92656
Chulho Park	officer: CHIEF TECHNOLOGY OFFICER	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King	director
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun	10 percent owner, officer: Chief Medical Officer	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao	10 percent owner	701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang	10 percent owner	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds	director	C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd	director	C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar	officer: Chief Financial Officer	505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha	officer: Controller	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080